These results suggest that ARID1B contributes to oncogenic transcriptional programs in breast cancer, and that its inhibition by targeting nuclear import or SWI/SNF activity leads to a shift toward a tumor‐suppressive transcriptional state. Here, ARID1B is linked to breast carcinoma.